| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
| [2] |
中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021年版)[J]. 中国癌症杂志, 2021, 31(10): 954-1040.
|
| [3] |
《乳腺癌HER2检测指南(2019版)》编写组. 乳腺癌HER2检测指南(2019版)[J]. 中华病理学杂志, 2019, 48(3): 169-175.
|
| [4] |
Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer[J]. N Engl J Med, 2022, 387(1): 9-20.
|
| [5] |
中国抗癌协会国际医疗与交流分会, 中国医师协会肿瘤医师分会乳腺癌学组. 人表皮生长因子受体2低表达乳腺癌临床诊疗共识(2022版)[J]. 中华肿瘤杂志, 2022, 44(12): 1288-1295.
|
| [6] |
Guo Y, Xie X, Tang W, et al. Noninvasive identification of HER2-low-positive status by MRI-based deep learning radiomics predicts the disease-free survival of patients with breast cancer[J]. Eur Radiol, 2024, 34(2): 899-913.
|
| [7] |
Ramtohul T, Djerroudi L, Lissavalid E, et al. Multiparametric MRI and radiomics for the prediction of HER2-zero, -low, and -positive breast cancers[J]. Radiology, 2023, 308(2): e222646.
|
| [8] |
Tarantino P, Hamilton E, Tolaney SM, et al. HER2-low breast cancer: pathological and clinical landscape[J]. J Clin Oncol, 2020, 38(17): 1951-1962.
|
| [9] |
Schettini F, Chic N, Brasó-Maristany F, et al. Author correction: clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer[J]. NPJ Breast Cancer, 2023, 9(1): 32.
|
| [10] |
Zhang G, Ren C, Li C, et al. Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status[J]. BMC Med, 2022, 20(1): 142.
|
| [11] |
Xu H, Han Y, Wu Y, et al. Clinicopathological characteristics and prognosis of HER2-low early-stage breast cancer: A single-institution experience[J]. Front Oncol, 2022, 12: 906011.
|
| [12] |
Won HS, Ahn J, Kim Y, et al. Clinical significance of HER2-low expression in early breast cancer: A nationwide study from the Korean Breast Cancer Society[J]. Breast Cancer Res, 2022, 24(1): 22.
|
| [13] |
Li Y, Abudureheiyimu N, Mo H, et al. In real life, low-level HER2 expression may be associated with better outcome in HER2-negative breast cancer: A study of the national cancer center, China[J]. Front Oncol, 2022, 11: 774577.
|
| [14] |
Denkert C, Seither F, Schneeweiss A, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials[J]. Lancet Oncol, 2021, 22(8): 1151-1161.
|
| [15] |
de Moura Leite L, Cesca MG, Tavares MC, et al. HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer[J]. Breast Cancer Res Treat, 2021, 190(1): 155-163.
|
| [16] |
Gianni L, Lladó A, Bianchi G, et al. Open-label, phase Ⅱ, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer[J]. J Clin Oncol, 2010, 28(7): 1131-1137.
|
| [17] |
Press MF, Finn RS, Cameron D, et al. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and Lapatinib efficacy in women with metastatic breast cancer[J]. Clin Cancer Res, 2008, 14(23): 7861-7870.
|
| [18] |
Burris HA 3rd, Rugo HS, Vukelja SJ, et al. Phase Ⅱ study of the antibody drug conjugate Trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER-2)-positive breast cancer after prior HER2-directed therapy[J]. J Clin Oncol, 2011, 29(4): 398-405.
|
| [19] |
Krop IE, LoRusso P, Miller KD, et al. A phase Ⅱ study of Trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with Trastuzumab, Lapatinib, an anthracycline, a taxane, and capecitabine[J]. J Clin Oncol, 2012, 30(26): 3234-3241.
|
| [20] |
Banerji U, van Herpen CML, Saura C, et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: A phase 1 dose-escalation and dose-expansion study[J]. Lancet Oncol, 2019, 20(8): 1124-1135.
|
| [21] |
Wang J, Liu Y, Zhang Q, et al. RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer：A pooled analysis of two studies[J]. J Clin Oncol, 2021, 39(15): 1022.
|
| [22] |
Schmid P, Cortés J, Marmé F, et al. Sacituzumab govitecan efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer by HER2 immunohistochemistry status in the phase Ⅲ TROPiCS-02 study[J]. Ann Oncol, 2022, 33 (suppl 7): S88–S121.
|
| [23] |
Mittendorf EA, Ardavanis A, Symanowski J, et al. Primary analysis of a prospective, randomized, single-blinded phase Ⅱ trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence[J]. Ann Oncol, 2016, 27(7): 1241-1248.
|
| [24] |
Clifton GT, Hale D, Vreeland TJ, et al. Results of a randomized phase Ⅱb trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to prevent recurrences in patients with high-risk HER2 low-expressing breast cancer[J]. Clin Cancer Res, 2020, 26(11): 2515-2523.
|
| [25] |
Yi M, Wu Y, Niu M, et al. Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer[J]. J Immunother Cancer, 2022, 10(12): e005543.
|
| [26] |
Wu Y, Zhong R, Ma F. HER2-low breast cancer: novel detections and treatment advances[J]. Crit Rev Oncol Hematol, 2023, 181: 103883.
|
| [27] |
Fernandez AI, Liu M, Bellizzi A, et al. Examination of low ERBB2 protein expression in breast cancer tissue[J]. JAMA Oncol, 2022, 8(4): 1-4.
|
| [28] |
Lambein K, Van Bockstal M, Vandemaele L, et al. Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: clinical and pathobiological relevance[J]. Am J Clin Pathol, 2013, 140(4): 561-566.
|